


## Supplementary Figure S5



**Supplementary Figure S5. Lack of correlation between ctHPV16DNA clearance at week 6 and persistent/recurrent disease.** Percentage clearance of ctHPV16DNA (relative to pre-treatment levels) is plotted, with >95% clearance indicated by the blue shaded box. Red dots indicate patients that developed persistent/recurrent disease. Higher amounts of residual ctHPV16DNA at the end of week 6 did not enrich for patients at higher risk of developing persistent/recurrent disease.